Doxycycline Hyclate (WC2031)

Catalog No.S4163 Synonyms: Doxycycline hydrochloride hemiethanolate hemihydrate

For research use only.

Doxycycline Hyclate (WC2031, Doxycycline hydrochloride hemiethanolate hemihydrate) is a member of the tetracycline antibiotics group, and is commonly used to treat a variety of infections. It is also an inhibitor of matrix metallo-proteinases (MMP).

Doxycycline Hyclate (WC2031) Chemical Structure

CAS No. 24390-14-5

Selleck's Doxycycline Hyclate (WC2031) has been cited by 28 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Doxycycline Hyclate (WC2031, Doxycycline hydrochloride hemiethanolate hemihydrate) is a member of the tetracycline antibiotics group, and is commonly used to treat a variety of infections. It is also an inhibitor of matrix metallo-proteinases (MMP).
Targets
MMP [6]
In vitro

Doxycycline hyclate 10% (DOXY) has significant toxicity effects on osteoblast cells compared to the control group with a mean cell viability of 84%. Doxycycline hyclate 10% (DOXY) results in a significantly higher alkaline phosphatase activity (approximately 56%) than the control in osteoblasts. Doxycycline hyclate 10% (DOXY) seems to slightly altered the morphology of the osteoblasts. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SW1353 MVrGeY5kfGmxbjDhd5NigQ>? MX[1NEB2VQ>? NX7ZU2x7UW6qaXLpeIlwdiCxZjDJUE0yNWKndHGtbY5lfWOnZDDNUXAyOyCycn;keYN1cW:wIHnuJIh2dWGwIGPXNVM2OyClZXzsd{BifCB3MDD1US=> NEPue4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K2O|IzPyd-MUeyOlczOjd:L3G+
K-12 BW25113 MmjrRoFkfGW{aXPp[IFtKGG|c3H5 MlvCNlQhcHK| M{\0TWJi[3SncnnjbYRidCCjY4Tpeol1gSCjZ3HpcpN1KHmjZmGg[4Vv\S2mZX\pZ4lmdnRiRYPjbIVzcWOqaXGgZ49tcSCNLUGyJGJYOjVzMUOgZolw\mmubTDhd5Nme3OnZDDhd{Btd2dicnXkeYN1cW:wIH;mJJZq[WKuZTDj[YxteyCjZoTldkAzPCCqcoO= M3rvNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C3N|c2Lz5zOUOwO|M4PTxxYU6=
K-12 BW25113 MXTCZYN1\XKrY3nkZYwh[XO|YYm= MXiyOEBpenN? M1TDSmJi[3SncnnjbYRidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUy1zMjDCW|I2OTF|IHLpc4ZqdG1iaHHyZo9zcW6pIIDDRVI1ViCydHHjPlp6[W[TIIDsZZNucWRiYYPz[ZN{\WRiYYOgcI9oKHKnZIXjeIlwdiCxZjD2bYFjdGViY3XscJMh[W[2ZYKgNlQhcHK|IIDy[ZRz\WG2ZXSge4l1cCB3IIXNJI9nKEmSVFeg[o9zKDRiaILz NVuzWVhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFc{PzVpPkG5N|A4Ozd3PD;hQi=>
K562 NXXGNGlES3m2b4TvfIlkcXS7IHHzd4F6 NV\EZYJuPzJiaILz NHi1Om5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBndG:5IHP5eI9u\XS{eTygTWM2OCB;IEG1JO69VS5? M2jTelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEiyOFc3Lz5zOUS4NlQ4PjxxYU6=
HepG2 M4r2fGN6fG:2b4jpZ4l1gSCjc4PhfS=> NF\sZ|A4OiCqcoO= M{\LVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzOCEQvF2u M13pbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEiyOFc3Lz5zOUS4NlQ4PjxxYU6=
THP1 MmOySpVv[3Srb36gZZN{[Xl? M1W0b3NmdGWldHn2bZR6KGmwZHX4MEBz[XSrbzDv[kBKSzVyIH\vdkBpfW2jbjDUTHAyKGOnbHzzJJRwKEmFNUCg[o9zKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTygTWM2OCB;IEOuNUDPxE1w MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEe4NUc,OTl5NEi3PFE9N2F-
THP1 NEnYbXhEgXSxdH;4bYNqfHliYYPzZZk> MVW3NkBpenN? M4nNT2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHRJWDFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dpktKEmFNUCgQUAzOCEQvF2u M{fhVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O|gyLz5zOUe0PFc5OTxxYU6=
K562 MVLDfZRwfG:6aXPpeJkh[XO|YYm= NH70eIM4OiCqcoO= MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDmcI94KGO7dH;t[ZRzgSxiSVO1NEA:KDF3IN88UU4> M{XreFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUK2NVc{Lz5zOUmyOlE4OzxxYU6=
HepG2 NWT5NnJGS3m2b4TvfIlkcXS7IHHzd4F6 MV63NkBpenN? MlvtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIxKM7:TT6= MkT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Mk[xO|MoRjF7OUK2NVc{RC:jPh?=
HepG2 M33lUGN6fG:2b4jpZ4l1gSCjc4PhfS=> NX\xfXRLPzJiaILz NXPuOoxOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDJyIN88UU4> NFW4PYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe0NVE{OSd-MkG3OFEyOzF:L3G+
Neuro2a NXrYfWhTTnWwY4Tpc44h[XO|YYm= MnvyNUB2VQ>? MmD5SIVkemWjc3WgbY4hPy2GSFOgcIV3\Wy|IHnuJGRp[3J5LXTl[olkcWWwdDDtc5V{\SCQZYXyc|JiKGOnbHzzJIF1KDFidV2gZpkhVENvTWOvS2MuVVNiYX7hcJl{cXN? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OU[1O{c,OjZ5OEm2OVc9N2F-
HepG2 NHfheZREgXSxdH;4bYNqfHliYYPzZZk> MoLGO|IhcHK| MkfiR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhS0N3MDC9JFIxKM7:TT6= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF3NUS2N{c,OjdzNUW0OlM9N2F-
HepG2 MVnDfZRwfG:6aXPpeJkh[XO|YYm= MVu3NkBpenN? NXLNfotyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGNEPTBiPTCyNEDPxE1w NYfGTo43RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2OVQ{QTVpPkK3OlU1Ozl3PD;hQi=>
CD NH7mdHZCdnSrYnHjeIVzcWGuIHHzd4F6 Mn;mNlUhfWdxbXy= M4r5TFczKGi{cx?= NGPIbXdCdnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3RiUnnjb4V1fHOrYTDwdo94[Xqna3npJJN1ei5iQoLlbY5tKGmwZnXjeIVlKGmwIFPEJJJifCCycnntZZJ6KHC3bH3vcoFzgSC4YYPjeYxieiCnbnTveIhmdGmjbDDj[YxteyCjc4Pld5Nm\CCjczDiZYN1\XKrYXygd4hieGViY3jhcodmKGG2IEK1JJVoN22uIH3lZZN2emWmIEeyJIhzeyCyb4P0JIlv\mWldHnvckBjgSCKb3XjbJN1KDN|MkW4M5Bp[Wyub3nkbY4he3SjaX7pcoch[mG|ZXSg[ox2d3J? Ml;lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyOEmzOVAoRjJ6MEi5N|UxRC:jPh?=
A673 MYHxTHRUKGG|c3H5 M3rBW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| M2K1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NY\1ephDeUiWUzDhd5NigQ>? M1SxO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= NFHn[VU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
skeletal myoblast cells MoDVR5l1d3SxeHnjbZR6KGG|c3H5 M1W1W2RPTEl8IFP5eI91d3irY3n0fUBqdiCYaYTyc{whPzJiaH;1dkwhcW5icnH0JJNs\WyndHHsJI16d2KuYYP0JINmdGy|LDDJR|UxKD1iMUSuOFkh|ryPLh?= MlroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQ{Oy9pPlPoSW1DVDxxYU6=
Assay
Methods Test Index PMID
Western blot AKT / BCL6 / Cyclin E / HDAC2 / HDAC3 / NEMO / TYK2 / RIPK1 ; HSP70 / HSP90 ; pATM / ATM 26142707 23282955
Immunofluorescence E-cadherin / Vimentin 29285218
In vivo Doxycycline hyclate is an effective treatment for acute E. canis infection in dogs. [2] Doxycycline hyclate (5 mg/kg, orally) decreases the collagenase activity in corneas obtained from rabbits. Doxycycline hyclate (5 mg/kg, orally) promotes corneal reepithelialization in the rabbit alkali-burn model, a result, perhaps, of the drug's ability to inhibit excessive collagenase activity. [3] Doxycycline hyclate results in 43% of prophylaxis in orally treated mice, in contrast, the sustained-release doxycycline hyclate completely protects mice from infection and resultant pathology. [4] Doxycycline hyclate results in bioavailability of 70%, Cmin of 1 mg/L, Cmax of 2.3 mg/L and elimination half-life of 7 hours in calves with immature rumen function. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 512.94
Formula

C22H24N2O8.1/2C2H6O.HCl.1/2H2O

CAS No. 24390-14-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCO.CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04838717 Not yet recruiting Drug: BPG|Drug: Doxycycline Syphilis Assistance Publique - Hôpitaux de Paris November 2021 Phase 3
NCT05111002 Not yet recruiting Drug: Lefamulin|Drug: Doxycycline Mycoplasma Genitalium Infection University of Washington|Nabriva Therapeutics AG November 30 2021 Phase 1|Phase 2
NCT04860505 Recruiting Drug: Doxycycline|Drug: Biktarvy Sexually Transmitted Diseases Emory University|Centers for Disease Control and Prevention May 20 2021 Phase 4
NCT04762134 Not yet recruiting Drug: Doxycycline Hyclate Bacterial Sexually Transmitted Diseases Jonathan Troy Grennan|Canadian Institutes of Health Research (CIHR)|British Columbia Centre for Disease Control April 1 2021 Phase 2|Phase 3
NCT04597424 Recruiting Drug: Experimental: doxycycline|Biological: Bexsero® vaccine Unsafe Sex|Risk-Taking ANRS Emerging Infectious Diseases January 19 2021 Phase 3
NCT04686799 Recruiting Drug: Doxycycline Hyclate 20 MG Lateral Epicondylitis|Lateral Epicondylitis Left Elbow|Lateral Epicondylitis Right Elbow|Lateral Epicondylitis Unspecified Elbow|Lateral Epicondylitis (Tennis Elbow) Bilateral Hospital for Special Surgery New York December 3 2020 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Doxycycline Hyclate (WC2031) | Doxycycline Hyclate (WC2031) supplier | purchase Doxycycline Hyclate (WC2031) | Doxycycline Hyclate (WC2031) cost | Doxycycline Hyclate (WC2031) manufacturer | order Doxycycline Hyclate (WC2031) | Doxycycline Hyclate (WC2031) distributor